Related Experiment Video
Updated: May 7, 2026

07:45
Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
Published on: October 25, 2024
1.0K
Automatic extraction of PET RANO criteria with an externally validated deep learning model: Application to [18F]FDOPA
Timothée Zaragori1,2, Laura Rozenblum3,4, Guido Rovera5
1CHRU-Nancy, Inserm, Université de Lorraine, CIC 1433, Innovation Technologique, Nancy, France.
Neuro-Oncology
|May 6, 2026
Summary
A deep learning model accurately segments gliomas on [18F]FDOPA PET scans, enabling reliable quantitative assessment for treatment monitoring. This automated approach supports wider clinical use of amino-acid PET in neuro-oncology.
Area of Science:
- Neuro-oncology
- Medical Imaging
- Artificial Intelligence
Background:
- Accurate glioma segmentation on amino acid PET is crucial for quantitative tumor assessment during treatment.
- This study focuses on developing an automated deep learning model for extracting PET RANO criteria from [18F]FDOPA PET scans.
Purpose of the Study:
- To develop and validate a deep learning model for automated segmentation of gliomas on [18F]FDOPA PET.
- To assess the model's performance in extracting quantitative PET RANO criteria.
Main Methods:
- A 3D U-Net model was trained on 530 [18F]FDOPA PET scans from three European centers.
- The model segmented tumor and healthy brain volumes, with performance evaluated using Dice coefficients.
- Quantitative agreement for PET RANO criteria, TBRs, and MTV was assessed at the lesion level.
Main Results:
- The model achieved high Dice coefficients (0.851–0.925) across training, validation, and test sets.
- Excellent agreement was found with expert quantification for MTV, TBRmax, and TBRmean (ICC > 0.93).
- Over 97% of measurable lesions were correctly identified.
Conclusions:
- The developed [18F]FDOPA PET deep learning model shows robust multicenter performance.
- The model enables fully automated and reproducible quantification of gliomas.
- This supports broader clinical adoption of amino-acid PET in neuro-oncology.

